Illumina, Inc. ILMN, a major developer of life science tools for large-scale genetic analysis, has launched the BaseSpace Informatics suite to facilitate precision medicine and genomics research. With this suite, the company aims to provide a comprehensive enterprise genomics platform that offers greater capabilities than before.According to Illumina, this is the first cloud-based, sample-to-answer informatics infrastructure that works on critical issues in genomic data processing and analysis by reducing the time from sample submission to answer. It improves the overall accuracy of the results without the need to integrate point solutions from multiple vendors. The BaseSpace suite is best for a full range of labs that includes clinical and translational labs, research institutions or any other entity that generates, analyzes and interprets genomic data. The system provides pre-configured workflows and analysis pipelines and can be custom configured for use with individualized workflows and analysis pipelines.The BaseSpace suite is consistent with Illumina’s ongoing strategy to launch highly competitive products in order to strengthen its foothold in the multi-billion dollar gene sequencing market. We note that, for market expansion, the company’s core area of focus remains reproductive and genetic health, for which Illumina seeks to boost its portfolio by providing the verifi laboratory-developed non-invasive prenatal test (NIPT).The reproductive and genetic health market is developing rapidly on a global scale, which has allowed the company to witness solid growth of more than 50% from its NIPT service revenues in the fourth quarter. Management believes the availability of Illumina’s next-generation solution VeriSeq NIPT will enhance its global opportunity. Currently, Illumina is in the final stages of the European regulatory process for the software and expects to receive the CE mark shortly.Zacks Rank Currently, Illumina has a Zacks Rank #3 (Hold). Some better-ranked medical stocks are Actelion Ltd. ALIOF, Anika Therapeutics Inc. ANIK and AMAG Pharmaceuticals, Inc. AMAG. All the three stocks sport a Zacks Rank #1 (Strong Buy).Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AMAG PHARMA INC (AMAG): Free Stock Analysis Report ILLUMINA INC (ILMN): Free Stock Analysis Report ACTELION LTD (ALIOF): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research